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Hantavirus pulmonary syndrome (HPS) is an acute zoonotic disease transmitted primarily
through inhalation of virus-contaminated aerosols. Hantavirus infection of endothelial
cells leads to increased vascular permeability without a visible cytopathic effect. For this
reason, it has been suggested that the pathogenesis of HPS is indirect with immune
responses, such as cytokine production, playing a dominant role. In order to investigate
their potential contribution to HPS pathogenesis, we analyzed the serum of hantavirus-
infected subjects and healthy controls for 68 different cytokines, chemokines, angiogenic,
and growth factors. Our analysis identified differential expression of cytokines that
promote tissue migration of mononuclear cells including T lymphocytes, natural killer
cells, and dendritic cells. Additionally, we observed a significant upregulation of cytokines
known to regulate leukocyte migration and subsequent repair of lung tissue, as well as
cytokines known to increase endothelial monolayer permeability and facilitate leukocyte
transendothelial migration. Conversely, we observed a downregulation of cytokines
associated with platelet numbers and function, consistent with the thrombocytopenia
observed in subjects with HPS. This study corroborates clinical findings and extends our
current knowledge regarding immunological and laboratory findings in subjects with HPS.
Keywords: hantavirus pulmonary syndrome, serum, cytokines, chemokines, growth factors, immune response,
hantaviruses
Introduction
Hantavirus pulmonary syndrome (HPS) is a severe life threatening disease caused by members of
the genus Hantavirus. In the United States, these members include Sin Nombre virus, Bayou virus,
Black Creek Canal virus, and New York virus, while South American members include Andes virus
and Laguna Negra virus (1–5). Although HPS was first diagnosed as a clinical entity in 1993 in
response to the four corners outbreak (6), retrospective studies have identified hantavirus-associated
fatalities as early as 1978 (7). HPS cases have been reported in 34 states with themajority occurring in
the Southwestern states; however, several have been reported in the Northwestern and Midwestern
states. Through April 2014, the Center for Disease Control and Prevention has confirmed 639 total
cases of HPS in the U.S., with the majority occurring in NewMexico (94 cases), Colorado (81 cases),
and Arizona (72 cases) (8). Although the prevalence of HPS is low in the U.S., 36% of all reported
HPS cases have resulted in death, underscoring the potential impact to public health.
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Clinically, HPS manifests with fatigue, fever, muscle pain,
headache, dizziness, nausea, and vomiting (9). Soon after onset,
individuals present with bilateral diffuse interstitial edema resem-
bling acute respiratory distress syndrome (10). Rapidly progress-
ing pulmonary edema, myocardial depression, and hypovolemia
are the leading cause of death (11). There is no specific treatment
for HPS; therefore, medical care is mainly supportive with early
diagnosis resulting in more successful outcomes.
Hantaviruses do not produce a visible cytopathic effect; con-
sequently, it is believed that cytokines produced by infected cells
either directly or indirectly lead to a compromised endothe-
lial monolayer, which in turn, leads to vascular leakage.
Indeed, increased numbers of cytokine-producing cells have been
observed in lung and spleen tissue of HPS cases (12). We as well
as others have demonstrated that endothelial cells produce the
chemokines, CCL5 and CXCL10, when infected with Sin Nombre
virus (13, 14). These cytokines are strong chemoattractants for
mononuclear leukocytes including monocytes, lymphocytes, and
natural killer (NK) cells (15, 16). Expression of these chemokines
may explain the postmortem observation of monocytic intersti-
tial pneumonia in fatal HPS cases; however, it remains to be
determinedwhether these chemokines are expressed during active
HPS. In contrast to CCL5 and CXCL10 and atypical of most viral
infections, in vitro culture studies show that only a slight upregu-
lation of type I interferon (IFN) is observed when endothelial cells
are infected with hantaviruses. These data are also consistent with
clinical observations that suggest that a robust IFN-α response is
not characteristic of hantavirus infection (17, 18).
Although limited data exist regarding cytokine expression in
subjects with HPS, a study by Borges et al. evaluated the con-
centrations of 11 serum analytes by ELISA. A cytokine pro-
file was reported that defined the differential expression of a
selected number of Th1 and Th2 cytokines (19). Specifically,
they observed significantly elevated levels of IL-6, IFN-γ, sIL-
2R, TNF-α, and decreased IL-10 when compared to controls,
suggesting that activation of Th1 andTh2-type immune responses
are involved. While ELISA is commonly used for such studies,
it has limitations such as the necessity of a large sample vol-
ume and this issue is compounded when one wishes to ana-
lyze multiple analytes. High-throughput multiplex analysis by
Luminex xMAP technology allows the simultaneous detection
and quantitation of many analytes and uses a small amount of
serum or plasma. In the present study, we utilized Luminex
xMAP technology to conduct a comprehensive evaluation of 68
different cytokines, chemokines, angiogenic, and growth factors
(hereafter referred to collectively as cytokines) in subjects with
HPS, including 38 cytokines previously not investigated in asso-
ciation with this disease. Changes in 40 cytokines were detected
in the serum of subjects with HPS when compared to healthy
controls; 25 cytokines were significantly upregulatedwhile15were
downregulated. A subset of these cytokines known to influence
the migration of mononuclear effectors was upregulated, as were
cytokines known to play a role in lungmicrobial defense and tissue
repair. Another subset of cytokines associated with thrombocyte
counts and function was downregulated. This study corroborates
clinical findings and extends our current knowledge by provid-
ing a more comprehensive basis for the immune responses and
morphology observed in laboratory and histological findings in
subjects with HPS.
Materials and Methods
Subjects
Twelve clinical diagnostic serum specimens collected from 2008
to 2012 by the Nevada State Health Laboratory (NSHL) and with
a confirmed diagnosis of HPS were utilized in this study. The
NSHL serves as a regional reference laboratory and routinely
screens subjects suspected of having HPS, by the presence of anti-
hantavirus antibodies. These deidentified diagnostic specimens
were deemed to be exempt from IRB approval by the University
of Nevada (UNR), Research Integrity Office (Reference #616225-
1) as meeting the exemption criteria defined by the Department
of Health and Human Services under Human Subject Research
Code 45 CFR 46.102(f). Information of eachHPS case was limited
to diagnosis, gender, and antibody titer range. Forty-two serum
samples from healthy individuals collected under informed con-
sent were used as controls (Human subjects protocol # B12-031).
Control subjects were chosen to be consistent with published
demographics of typical HPS cases regarding age and gender
(male to female ratio of 54–46%, respectively, and mean age of
39.4 years) (20).
HPS Screening
Serum anti-hantavirus antibody titers were evaluated by ELISA,
according to the methods described by Feldmann et al. (21).
Serum dilutions (1:100–1:6400) were tested for the presence of
anti-hantavirus IgG and IgM using recombinant nucleocapsid
protein supplied by the United States Centers for Disease Control
and Prevention (CDC, Atlanta, GA, USA). Subjects with antibody
titers greater than twofold above that of negative controls were
considered positive.
Multiplex Analysis
The levels of serum cytokines were analyzed using Bio-Plex (Bio-
Rad, Hercules, CA, USA) multiplex magnetic bead-based anti-
body detection kits following themanufacturer’s instructions. The
Bio-Plex Pro Human Chemokine Panel (40-Plex); Bio-Plex Pro
Human Th17 Cytokine Panel; Bio-Plex Pro Human Cytokine 27-
plex Panel; and Bio-Plex Human Cytokine 21-plex Panel were
used for analysis of a total of 68 analytes. Fifty microliters of
serum from each respective case and control was analyzed using
a Luminex 200 analyzer with MasterPlex CT control software
and MasterPlex QT analysis software (MiraiBio, San Bruno, CA,
USA). Standard curves for each analyte were generated using stan-
dards provided by manufacturer. Serum samples from HPS cases
were heat inactivated and tested for the presence of infectious
virus prior to Luminex analysis. The effect of heat inactivation
on cytokine stability was evaluated and those that could not be
normalized were excluded from analysis.
Statistical Analysis
Mann–Whitney non-parametric analysis was utilized to identify
differences in medians between HPS cases and controls. In addi-
tion, we performed classification analysis using the tree-based
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ensemble machine learning algorithm Random Forest (RF) (22).
For this analysis, 500 random trees were built using six predictors
for each node, and auto-bootstrap out-of-bag sampling was used
for testing the model as previously described (23).
Results
Anti-Hantavirus Titer in HPS Serum
Twelve serum samples from subjects suspected of having han-
tavirus infection were tested for the presence of anti-hantavirus
IgG and IgM antibodies. Antibody titers twofold greater than
those of the control samples were considered diagnostic for han-
tavirus infection (Table 1). Previous reports suggest that anti-
hantavirus IgM and IgG change with disease progression (24,
25). As reported by MacNeil and coworkers, early stage HPS is
characterized by high IgM titers that peak within 11–14 days after
onset whereas cases with early stage HPS often have no SNV-
specific IgG titer (24). In contrast to IgM titers, median IgG titers
typically displayed an increasing trend for a longer interval after
the onset of disease. In light of the deidentified nature of our HPS
cases, we used antibody titers to assess the stage of their illness.
Six of our cases had high serum titer of IgM while IgG levels
were low or undetectable, indicative of early stage disease. For the
remaining six cases, high serum titers were observed for both IgG
and IgM, consistent with late onset HPS.
Differential Expression of Serum Cytokine in HPS
Cases
A total of 68 serum cytokines were measured for HPS cases and
controls (Tables 2–4). To the best of our knowledge, 38 of these
cytokines were previously uninvestigated in the context of HPS
(indicated by an asterisk in Tables 2–4). A significant increase
in the serum levels of 25 of 68 (36.7%) cytokines were observed
for the HPS cases when compared to healthy controls (Table 2).
The greatest difference was observed for IL-6, CXCL10, CX3CL1,
MIF, and MIG, all of which were upregulated fivefold over those
of controls (p< 0.001). In contrast, 15 of 68 (22.1%) cytokines
were downregulated in HPS cases when compared to controls
(Table 3), the greatest differences were observed for CXCL12,
CCL21, CCL22, CCL27, and sCD40L (p< 0.001). Additionally,
the majority of downregulated cytokines belonged to the home-
ostatic and inflammatory chemokine family. Of the 68 cytokines
TABLE 1 | Antibody titer in serum from HPS cases.
Subject IgM titer IgG titer Stage
1 >6400 <400 Early
2 >6400 <400 Early
3 >6400 <400 Early
4 >400 Negative Early
5 >400 Negative Early
6 >400 Negative Early
7 <6400 >6400 Late
8 <6400 >6400 Late
9 <6400 >6400 Late
10 <6400 >6400 Late
11 <6400 >6400 Late
12 <6400 >6400 Late
investigated, 28 (41.2%) were not statistically different when com-
paring cases and controls (Table 4).
Analysis of Serum Cytokines in Early vs. Late
Stage HPS
In order to investigate the possibility that differential expression
of cytokines occurs between subjects with early and late stage
HPS, we compared these two subgroups with each other and to
healthy controls. Surprisingly, we observed only five cytokines
to be differentially expressed between the two subgroups of HPS
TABLE 2 | Cytokines upregulated in HPS cases compared to healthy
controls.
Analyte Case (pg/mL),
n=12
Control (pg/mL),
n=41
p Value
Upregulated In HPS serum
IL-1α 537:7 95:0 179:12 15:7 0:0001
IL-2RA 455:3 84:6 177:3 7:3 0:0001
IL-2 11:7 3:6 4:7 0:8 0:005
IL-3 415:1 86:4 140:5 11:4 0:0001
IL-6 87:9 22:7 10:8 2:0 0:0001
IL-10 49:2 31:5 15:7 1:1 0:05
IL-12(p40) 927:3 175:1 280:7 22:9 0:0001
IL-17A* 23:3 6:8 7:5 0:2 0:0001
IL-17F* 74:3 19:3 17:9 4:8 0:0001
IL-18* 1651:6 495:1 803:6 66:7 0:006
IL-22* 42:1 12:1 22:7 0:5 0:004
CCL23* 705:9 102:5 375:7 37:6 0:0004
CXCL10 2834:2 913:5 197:8 18:8 0:0001
CX3CL1* 1456:6 321:2 241:3 13:2 0:0001
GM-CSF 55:3 9:7 14:2 2:5 0:0001
M-CSF 4811:7 167:7 415:1 26:5 0:0001
VEGF 179:2 122:7 48:8 6:1 0:05
MIF* 4779:9 2229 540:6 70:5 0:001
CXCL9* 2702:7 891 355:0 93:0 0:0001
TNFβ 227:9 26 147:9 12:9 0:007
IFNα 191:9 26:2 123:6 9:8 0:005
LIF* 346:7 40:9 216:9 10:7 0:0001
b-NGF* 122:0 13:8 98:3 3:9 0:03
SCF* 1180:8 233:9 469:3 30:9 0:0001
TRAIL* 391:9 82:4 266:7 14:8 0:02
TABLE 3 | Cytokines downregulated in HPS cases compared to healthy
controls.
Analyte HPS (pg/mL),
n=12
Control (pg/mL),
n=41
p Value
Downregulated in HPS serum
CCL1* 41:7 0:3 43:3 0:4 0:03
CCL5 1210:5 230 5520:3 670 0:001
CCL11 18:5 0:9 47:1 2:6 0:0001
CCL13* 37:1 10:2 135:0 14:1 0:0005
CCL17* 70:4 31:5 241:4 22:3 0:0004
CCL19* 156:2 58:9 418:5 38:1 0:001
CCL21* 979 193 3504:6 119 0:0001
CCL22* 276:2 101 1112:8 60:4 0:0001
CCL24* 356:7 93:8 597:8 49:5 0:02
CCL26* 16:4 2:5 27:6 1:9 0:005
CCL27* 319:8 65:7 1411:4 79:9 0:0001
CXCL6* 25:7 44 48:2 2:3 0:0002
CXCL12* 166:7 32:7 2367:3 104:3 0:0001
CXCL16* 183:4 44:0 618:3 27:9 0:0001
sCD40L 89:3 54:4 2014:2 128 0:0001
Frontiers in Immunology | www.frontiersin.org August 2015 | Volume 6 | Article 4323
Morzunov et al. Multiplex cytokine analysis in HPS
TABLE 4 |No significant difference in cytokine expression between HPS and
healthy controls.
Analyte HPS,
N=12 (pg/mL)
Healthy control,
n=41 (pg/mL)
p Value
IL-1 4:59 0:1 4:8 0:2 0:52
IL-1RA 93:7 50:7 50:4 7:4 0:15
IL-1β 2:7 0:1 7:9 1:9 0:1
IL-4 64:9 5:2 78:4 5:2 0:18
IL-5* 6:3 0:6 5:9 0:1 0:27
IL-7 5:3 2:1 5:5 0:5 0:9
IL-9* 9:9 1:7 19:7 11:9 0:66
IL-13 8:7 0:5 8:9 0:34 0:59
IL-15 9:7 4:1 5:7 0:07 0:07
L-16* 252:2 53:4 317:2 40:9 0:4
IL-21 30:7 8:7 30:1 6:0 0:96
IL-23 102:6 25:3 95:1 17:4 0:83
IL-25* 1:6 0:3 2:4 0:3 0:2
IL-31* 18:5 3:2 21:4 2:2 0:49
IL-33* 402:6 125:7 723:3 100:0 0:11
CCL3 18:3 3:7 43:9 9:5 0:15
CCL7* 196:9 27 169:1 23:1 0:55
CCL8 75:8 11:3 95:8 6:8 0:15
CXCL1* 215:9 34:9 232:4 13:4 0:6
CXCL2* 236:8 37:7 302:1 25:3 0:2
CXCL5* 1085:8 230:1 798:1 90:6 0:43
CXCL11* 23:5 5:2 41:3 10 0:35
FGF* 14:8 1:3 20:7 2:7 0:24
GCSF 26:2 13 26:4 3:3 0:98
HGF* 973:7 284:6 869:9 82:4 0:64
IFNγ 20:1 5:0 15:4 1:6 0:24
DCGF-β* 6605:8 1808 4692:7 353:1 0:1
PDGF 889:9 302 1095:5 62:1 0:29
cases (Table 5). Of these, median IL-33 and CXCL6 levels were
greater in the early stage subjects whereasmedianCCL23, CXCL1,
and TNF-β were greater in the late stage subjects. As expected,
differences in cytokine expression between subgroups and con-
trols were consistent with differences observed between total HPS
cases and controls (data not shown).
Classification of Cytokines by Importance
Given the complex interactions of cytokines with immune and
non-immune cells, clarification of how distinct cytokines con-
tribute to a pathological situation is often difficult to resolve.
In order to provide insight into this issue, we implemented the
machine logic algorithmRF to analyze our data set and potentially
identify the most important cytokines that define this disease.
For our analysis, 500 random decision trees were constructed
with six predictors at each node, and auto-bootstrap out-of-bag
sampling was implemented to test the accuracy of model. This
model accurately identified HPS cases with 100% specificity and
73.81% sensitivity (Table 6). The 10 most significant cytokines
for delineating HPS in decreasing order of importance are: M-
CSF, CXCL16, sCD40, CXCL12, CCL22, IL-1a, CCL21, IL-12p40,
CCL17, and IL-1b.
Discussion
The microvascular endothelium is principal target of hantavirus
infection in humans and its infection in lung tissue results in
significant pathology (26). Infection of endothelial cells leads
to increased vascular permeability without an observable cyto-
pathic effect; therefore, the pathogenesis of HPS is likely indirect
with immune responses, such as cytokine production, playing an
important role. The cytokines that we observed to be upregulated
in the serum of HPS cases are involved in a number of antivi-
ral defense mechanisms including proliferation, maturation, and
activation of leukocytes, as well as survival of leukocytes, and
regulation of endothelial monolayer permeability (Table 2). High
levels of IL-1α, IL-6, MIF, and TNF-β suggest a strong proin-
flammatory milieu in the serum of HPS cases, thus promoting
both inflammation and activation of immune responses. We also
observed stem cell proliferation factors to be upregulated, poten-
tially promoting the proliferation and differentiation of subsets
of immune effector cells. For example, proliferation of myeloid
progenitors is strongly supported by IL-3, GM-CSF, and M-CSF.
Increased serum concentrations of GM-CSF and M-CSF also
suggest proliferation of monocytes and granulocytes (neutrophils,
eosinophils, and basophils). Upregulation of the pluripotent fac-
tor, SCF, was also observed in association with HPS, suggesting
increased proliferation of T lymphocytes, NK cells, and dendritic
cells.
We observed a subset of 15 serum cytokines to be downregu-
lated in our HPS cases (Table 4). Twelve of these cytokines are
involved in chemotaxis of lymphocytes, such as B cells, T cells, and
NK cells, to sites of infection. Some of these cytokines, including
CCL22, CXCL12, and CCL17, are associated with activation of
Th2-type immunity and are potent recruiters of Th2 cells to the
lungs, as well as activators of pre-B cells (27–29). A number
of cytokines identified as differentially expressed in the present
study are consistent with putative immune responses of lung
tissue. For example, we observed the upregulation of serum IL-
17F, CXCL16, and IL-22, which are involved in the regulation
of leukocyte migration into lung tissue, as well as lung tissue
repair (30–33). Upregulation of IL-17F has also been observed in
the lung tissue of asthmatic cases and its level positively corre-
lated with disease severity (30, 34, 35). Overexpression of IL-17F
promotes neutrophil infiltration and increased airways sensitivity
and thus has a significant impact on lung function (35). IL-22
is considered a key cytokine for mucosal tissue repair (36) and
by activating antimicrobial responses in lung epithelial cells; it
has been shown to be critical for host defense as well. Also, IL-
22 promotes lung epithelial cell proliferation (37) and therefore,
based on our analyses, the cytokine profile observed in our HPS
cases is consistent with a pulmonary antimicrobial response and
subsequent mononuclear cell migration into the lung.
The serum cytokine profile observed in our HPS subjects also
suggests a mobilization of mononuclear immune effector cells
(Table 2). IL-12(p40) is an autocrine chemoattractant released
by activated macrophages and promotes Th1-type immunity (38,
39). Additionally, serum levels for several potent T lymphocyte
and NK chemoattractants were upregulated, including CXCL10,
MIG, and CCL23 (15, 16, 40, 41). MIF and VEGF, which are
regulators of mononuclear cell transendothelial migration, were
upregulated as well. Migration of leukocytes can also be facili-
tated by the upregulation of adhesion molecules on the surface of
endothelial cells in response to VEGF, IL-1α, and IL-6 (42, 43).
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TABLE 5 | Serum cytokine profile during early and late stages of HPS.
Analyte HPS early (pg/mL) HPS late (pg/nL) Control (pg/mL) p Value* p Value** p Value***
IL-1α 316:3 60:4 545 98:1 179:12 15:7 0:006 0:0001
IL-2RA 345:5 92:5 454:9 44:2 177:3 7:3 0:001 0:0001
IL-2 11:9 5:5 10:1 4:6 4:7 0:8 0:02
IL-3 269:3 39:8 331:6 87:2 140:5 11:4 0:0004 0:0002
IL-6 50:4 30:5 109:9 25:9 10:8 2:0 0:003 0:0001
IL-10 34:6 12:4 14:6 0:5 15:7 1:1 0:02
IL-12(p40) 613:9 77:3 815:1 196:3 280:7 22:9 0:0001 0:0001
IL-15 13:8 7:5 5:6 0:4 5:7 4:1 0:008
IL-17A 20:1 6:2 24:6 10:5 7:5 0:2 0:0001 0:001
IL-17F 61:0 24:8 52:7 10:7 17:9 4:8 0:009 0:03
IL-22 32:2 12:5 55:8 24:4 22:7 0:5 0:0005
IL-33 651:5 179:2 74:5 19:3 723:3 100 0:03
CCL5 1339:8 409:3 1168:7 182:5 5520:3 670 0:02 0:05
CCL11 20:0 1:3 17:5 0:6 47:1 2:6 0:0002 0:0009
CCL17 124:1 51:5 17:7 5:6 241:4 22:3 0:003
CCL19 250:1 64:4 126:3 32:9 319:6 38:1 0:02
CCL21 732:9 136:8 1185:5 303:1 3504:6 119 2.8E-11 0:0001
CCL22 458:6 159:4 108:5 39:9 1112:8 60:4 0:0004 0:0001
CCL23 489:8 112:4 990:7 122:7 375:7 37:6 0:0001 0:02
CCL24 229:5 53:3 608:2 180:2 597:8 49:5 0:007
CCL26 18:5 4:3 13:9 2:6 27:6 1:9 0:03
CCL27 306:4 91:9 391:2 97:1 1411:4 79:9 0:0001 0:0003
CXCL1 470:0 50:8 954:3 176:8 232:4 13:4 0:03 0:01
CXCL5 2005:6 1072:8 225:0 49:9 708:1 90:6 0:02
CXCL6 32:9 8:3 21:3 10:9 48:2 2:3 0:04 0:003
CXCL10 2785:2 146:2 3843:1 1266 197:8 18:8 0:0001 0:0001
CXCL12 191:1 47:2 181:0 42:6 2367:3 104:3 0:0001 0:0001
CXCL16 201:5 73:8 175:2 29:9 618:1 27:9 0:0001 0:0001
CX3CL1 1020:4 440:6 1710:3 309:1 241:3 13:2 0:0001 0:0001
GM-CSF 67:3 9:7 43:6 16:6 14:2 2:5 0:0001 0:005
DCGF-β 4611 1036:1 11215:6 3269 4692:7 353:1 0:0002
LIF 253:3 39:1 386:8 50:4 216:9 10:7 0:0001
M-CSF 1721:7 475:2 3563:8 1221:1 415:1 26:5 0:0001 0:0001
MIG 2924:6 1596:1 3152:6 2746:3 355:0 93:0 0:0003 0:0001
MIF 1977:3 540:6 666:2 200:9 540:6 70:5 0:008 0:0001
sCD40L 157:8 85:1 15:7 4:3 2014:2 128 0:0001 0:0001
SCF 798:8 207:6 1390:8 443:1 469:3 30:9 0:006 0:0001
TNFβ 167 16:4 226:9 16:1 147:9 12:9 0:04
VEGF 286:5 48:8 101:4 28:5 48.86.1 0:01 0:02
*p value early phase to control; **p value late phase to control; ***p value early to late phase.
MIF and VEGF promote expression of the adhesion molecules,
E-selectin, ICAM-1, and VCAM-1, and increase vascular perme-
ability (44, 45). Additionally, VEGF can decrease tight junctions
between endothelial cells enabling transmigration of immune
effector cells (42, 46). The observed increased serum levels of
CXCL1, which may lead to release of VEGF-A from hantavirus-
activated endothelial cells, further suggests that upregulation of
VEGF plays a role in HPS (47, 48).
Cytokines including CXCL10, MIF, MIG, IL-12(p40), IL-17A,
and CCL23 are known to promote proliferation and migra-
tion of mononuclear immune cells, such as T lymphocytes, NK
cells, monocytes, and dendritic cells (15, 49–51). Consequently,
our data support the previous observations of others whereby
mononuclear cell and immunoblasts are the principal cellu-
lar infiltrate in the lungs of HPS cases (12). Nevertheless, the
observed cytokine expression also is consistent with the activation
and migration of neutrophils. Previous studies suggest that the
cytokines, IL-17F, VEGF, CXCL1, GM-CSF, and IL-22, promote
neutrophil migration and lung tissue repair (52–54). These data
corroborate a previous report by Mori et al., who observed low-
level neutrophil infiltration in the lungs of HPS case (12). Interest-
ingly, serum level of CXCL8, the prototype neutrophil chemoat-
tractant, was not significantly elevated in the HPS cases in our
study; however, it was identified as one of the top 10 cytokines by
our RF analysis, suggesting its expression, or lack thereof, plays an
important role in HPS pathology. Our data further suggest that a
Th17 shift occurs in HPS (55). In the presence of IL-23, non-Th17
cells can produce IL-17 (56); however, we observed no differential
expression of serum IL-23 in HPS cases. Therefore, it is likely that
activated Th17 lymphocytes were the source of IL-17 in the serum
of our HPS cases.
Expression of IL-17 and IL-22 in HPS suggests a developing
antimicrobial state in the lung. It has been reported that IL-17
and IL-22 activate β-defensins and the S100 family of proteins
(52, 57). In vivo studies using knockout mice have demonstrated
that IL-17 and IL-22 are crucial for bacterial defense in the lung
(58, 59). Furthermore, it has been reported that IL-17R signaling
is mandatory for the establishment of an antibacterial response
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TABLE 6 | Random forest analysis of serum cytokines in HPS vs. controls.
Variable Score (%) Changes in HPS serum Variable Score (%) Changes in HPS serum
M-CSF 100:0000 Upregulated IL-17F 19:4733 Upregulated
CXCL16 98:7888 Downregulated CCL3 19:1369 Unchanged
sCD40L 96:8968 Downregulated CCL1 18:8358 Downregulated
CXCL12 85:5322 Downregulated CXCL11 18:5085 Unchanged
CCL22 78:4301 Downregulated DCGFB 17:9953 Unchanged
IL-1α 74:0061 Upregulated IL-4 17:7238 Unchanged
CCL21 70:3732 Downregulated IL-25 17:4077 Unchanged
IL-12(p40) 62:9938 Upregulated IL-33 16:6915 Unchanged
CCL17 62:8689 Downregulated CCL7 16:5016 Unchanged
IL-1β 61:4314 Unchanged TRAIL 15:7741 Upregulated
CCL5 61:0088 Downregulated IL-9 14:3617 Unchanged
IL-3 58:5351 Upregulated IL-18 12:0276 Upregulated
CCL13 58:0210 Downregulated IL-7 10:5668 Unchanged
CXCL9 52:4830 Upregulated IL-22 10:2808 Upregulated
CXCL10 50:3664 Upregulated CXCL2 9:3174 Unchanged
CCL11 48:5759 Downregulated MIF 8:8718 Upregulated
CCL27 46:5450 Downregulated IL-16 8:8434 Unchanged
CXCL5 46:0115 Unchanged b-NGF 7:9004 Upregulated
CX3CL1 45:6097 Upregulated IL-31 7:0565 Unchanged
GM-CSF 43:1944 Upregulated IL-10 6:3552 Upregulated
IFNα 41:2777 Upregulated CCL8 6:1227 Unchanged
LIF 40:7034 Upregulated IL-17A 5:3501 Upregulated
CCL24 39:4832 Downregulated INFG 4:9877 Unchanged
IL-2RA 38:9993 Upregulated GCSF 4:4335 Upregulated
PDGF 36:2886 Unchanged IL-1 4:1642 Unchanged
CCL19 34:6337 Downregulated FGF 4:0244 Unchanged
IL-6 31:5406 Upregulated HGF 3:9312 Unchanged
CXCL6 30:4604 Downregulated IL-1RA 3:5669 Unchanged
IL-15 25:5225 Unchanged CXCL1 3:3770 Unchanged
TNFβ 24:6500 Upregulated IL-5 2:6487 Unchanged
SCF 24:2768 Upregulated IL-23 2:2930 Unchanged
IL-2 22:9123 Upregulated VEGF 0:9825 Upregulated
CCL26 21:2675 Downregulated IL-13 0:0038 Unchanged
CCL23 20:7866 Upregulated
to M. pneumoniae, systemic fungal infection, B. fragilis, and E.
coli (60–63). Consistent with this statement, a protective role for
IL-22 was recently reported for experimental influenza A virus
infection (64).
We also observed a subset of cytokines involved in the reg-
ulation of platelet counts and function to be downregulated
in the serum of our HPS subjects, including sCD40L, CCL5,
CCL22, and CXCL12 (Table 3). Consistent with our observations
and the pathophysiology of HPS, CXCL12 and CCL22 act on
platelets to rapidly stimulate their adhesion (65), and CCL5 and
sCD40L are released by activated platelets (66–68). Wenzel and
coworkers reported that serum levels of sCD40L closely correlate
with platelets counts and that they are increased upon thrombo-
cyte transfusion (69). Viallard et al. also reported a correlation
between thrombocyte counts and serum sCD40L, implying that
it may be used as a surrogate marker for platelet counts (66).
Decreased thrombocyte counts are also well documented in asso-
ciation with HPS (2, 70) and our observation of downregulated
sCD40L presents a potential biomarker for the thrombocytopenia.
Notwithstanding, decreased serum CCL22 might also reflect the
development of the thrombocytopenia observed in HPS cases. It
has been shown that CCL22 is capable of aggregating platelets
in the presence of low concentrations of thrombin or adenosine
diphosphate (ADP), and can rapidly stimulate platelets adhesion
(65). It is noteworthy that endothelial cells do not produce this
cytokine; dendritic cells are themain source ofCCL22 (71). There-
fore, the thrombocyte aggregation and depletion observed in HPS
may be the result of cytokine-driven immune responses.
Serum levels of CCL21 and CCL27 were also downregulated
in the serum of our HPS subjects. These cytokines have tissue-
specific activity; for example, CCL21 orchestrates dendritic cell
and T cell trafficking to the lymph nodes (72–74) and CCL27 reg-
ulates migration of immune effector cells to the skin (75). Taken
together, these findings suggest that the cytokines expressed dur-
ing HPS promote lung tissue infiltration while reducing leukocyte
trafficking to other organs and tissues.
In order to investigate the contribution of each respective
cytokine to the disease process, we conducted classification anal-
ysis by RF. Of the 10 most important cytokines identified by
this analysis, 3 were significantly upregulated, as determined
by Mann–Whitney analysis; however, we also observed 6 to be
downregulated. This observation underscores the importance of
cytokine inhibition in the disease process and further suggests
that depressed serum cytokine expression may be an important
biomarker for monitoring disease progression.
Overall, the majority of downregulated serum cytokines were
associated with Th2-type immune activation; these included
CCL21, CCL17, CCL13, and CCL11. Furthermore, the cytokines
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significantly upregulated in HPS cases were those promoting
Th1-type immunity; these included CXCL9, CXCL10, and IL-
12(p40). The cytokines M-CSF, CXCL12, IL-3, LIF, GM-CSF,
CCL24, which facilitate activation, differentiation, and bone mar-
row mobilization of myeloid progenitors, were also identified by
RF analysis to differentiate HPS cases from controls. RF analysis
further identified chemokines associated with platelet aggregation
as important in differentiating cases from controls. Interestingly,
sCD40L and CXCL12 were ranked, respectively, as the third and
fourthmost import cytokine in ourRF analysis. Chemokines, such
as sCD40L, CXCL12, and CCL17, which are stored in platelet
granules, are released upon platelet aggregation, a process that is
critical in HPS pathology (2, 76–78). Accordingly, nadir platelet
counts in HPS may explain low serum CXCL1, CCL17, and
sCD40. Taken together, RF analysis supports the supposition that
HPS pathogenesis may be characterized by Th1-type immune
responses and thrombocytopenia.
In summary, our data suggest that HPS is characterized
by a serum cytokine profile that is consistent with putative
immune responses in lung tissue. Strong activation of mononu-
clear immune effectors including T lymphocytes, NK cells, and
dendritic cells is also suggested by this cytokine profile. Addition-
ally, our data imply that decreased counts and increased aggre-
gation of thrombocytes in HPS might be explained in part by
the immune response to viral infection. Lastly, to the best of our
knowledge, our data provide the first evidence of Th17 lympho-
cyte activation in association with HPS. The data presented in this
study are suggestive of putative in vivo immune mechanisms and
may identify the role of these cytokines in HPS pathophysiology;
however, future studies using animal models would be necessary
to definitively confirm their involvement.
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